

SUPPLEMENTARY DATA

Supplementary Table. Adjusted Hazard Ratios (95% Confidence Interval) for Incident CVD and CHD Events Among Subjects With Diabetes, According to Being at Individual and Composite Risk Factor Target, Stratified by Gender and Ethnicity

	Individual Risk Factor at Target			Number of Risk Factors at Target		
	BP < 130/80 mmHg vs. ≥ 130/80 mmHg	LDL-C < 2.6 mmol/l [100 mg/dl] vs. ≥ 2.6 mmol/l [100 mg/dl]	HbA1c < 53.0 mmol/mol [7%] vs. ≥ 53.0 mmol/mol [7%]	Any one (BP, LDL-C or HbA1c) at Target vs. None at Target	Any two (BP, LDL-C or HbA1c) at Target vs. None at Target	All three (BP, LDL-C and HbA1c) at Target vs. None at Target
CVD						
Gender						
Male, n=870	0.99 (0.78-1.25)	0.55 (0.41-0.72) §	0.66 (0.51-0.84) ‡	0.68 (0.52-0.91) †	0.53 (0.38-0.74) ‡	0.34 (0.20-0.60) ‡
Female, n=1,148	0.70 (0.55-0.89) †	0.85 (0.63-1.13)	0.59 (0.45-0.78) ‡	0.60 (0.46-0.77) §	0.47 (0.34-0.65) §	0.47 (0.25-0.89) *
p-Interaction	0.13	0.03	0.45	0.74		
Race						
African Americans, n=1,104	0.69 (0.54-0.88) †	0.71 (0.53-0.94) *	0.68 (0.52-0.89) †	0.55 (0.42-0.71) §	0.55 (0.40-0.76) ‡	0.23 (0.09-0.55) †
All Other Races, n=914	0.97 (0.77-1.23)	0.63 (0.47-0.84) †	0.60 (0.47-0.77) §	0.76 (0.57-1.00)	0.44 (0.32-0.63) §	0.49 (0.30-0.82) †
p-Interaction	0.09	0.57	0.39	0.04		
CHD						
Gender						
Male, n=870	0.97 (0.72-1.30)	0.53 (0.37-0.75) ‡	0.72 (0.54-0.97) *	0.77 (0.55-1.09)	0.55 (0.36-0.83) †	0.39 (0.19-0.78) †
Female, n=1,148	0.67 (0.49-0.92) *	0.70 (0.46-1.07)	0.56 (0.38-0.81) †	0.45 (0.32-0.64) §	0.36 (0.23-0.57) §	0.49 (0.22-1.10)
p-Interaction	0.33	0.49	0.24	0.21		
Race						
African Americans, n=1,104	0.61 (0.42-0.87) †	0.74 (0.49-1.12)	0.59 (0.40-0.88) †	0.50 (0.34-0.71) ‡	0.45 (0.28-0.72) ‡	0.30 (0.09-0.96) *
All Other Races, n=914	0.95 (0.72-1.25)	0.50 (0.35-0.71) §	0.68 (0.51-0.90) †	0.66 (0.48-0.91) *	0.43 (0.29-0.64) §	0.45 (0.24-0.81) †
p-Interaction	0.12	0.26	0.77	0.64		

Adjusted for age, gender, ethnicity, smoking status, HDL-C, BMI, family history of pre-mature CVD, hypertension medication, anti-diabetic medication and lipid-lowering medication (also include LDL-C and HbA1c for BP analysis; systolic/diastolic BP and HbA1c for LDL-C analysis; LDL-C and systolic/diastolic BP for HbA1c analysis).

*p < .05, † p < .01, ‡ p < .001, § p < .0001.

SUPPLEMENTARY DATA

Supplementary Figure. Flow-chart of sample selection from ARIC, MESA and JHS * Key risk factors include age, gender, race, SBP, DBP, LDL, HDL, HbA1c and BMI

